Dermira, Inc. a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today presented new findings from its glycopyrronium tosylate (formerly DRM04) Phase 3 clinical program. The data showed that when applied topically, the investigational therapy improved disease severity, reduced sweat production and was associated with improved quality of life outcomes for pediatric patients (ages 9 to 16) with primary axillary hyperhidrosis (excessive underarm sweating), compared to vehicle-treated patients.
These findings are consistent with results previously reported in adult patients (ages 17 and older). The data were featured in an oral presentation during the Late-Breaking Research Forums at the 76th Annual Meeting of the American Academy of Dermatology (AAD) in San Diego.
